Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study

J. Schetelig; J. Hoek; S. Stilgenbauer; J.M. Middeke; N.S. Andersen; C.P. Fox; S. Lenhoff; L. Volin; A. Shimoni; W. Schroyens; M. van Gelder; D. Bunjes; A. van Biezen; H. Baldauf; L.C. de Wreede; O. Tournilhac; N. Kroger; I. Yakoub-Agha; P. Dreger

doi:10.1038/s41409-020-01013-y

Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study

J. Schetelig^*
, J. Hoek
, S. Stilgenbauer
, J.M. Middeke
, N.S. Andersen
, C.P. Fox
, S. Lenhoff
, L. Volin
, A. Shimoni
, W. Schroyens
, M. van Gelder
, D. Bunjes
, A. van Biezen
, H. Baldauf
, L.C. de Wreede
, O. Tournilhac
, N. Kroger
, I. Yakoub-Agha
, P. Dreger

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	692-695
Number of pages	4
Journal	Bone Marrow Transplantation
Volume	56
Issue number	3
DOIs	https://doi.org/10.1038/s41409-020-01013-y
Publication status	Published - 1 Mar 2021

Keywords

blood
cll
european-society
follow-up
retrospective analysis
CLL
FOLLOW-UP
RETROSPECTIVE ANALYSIS
EUROPEAN-SOCIETY
BLOOD

Access to Document

10.1038/s41409-020-01013-yLicence: CC BY

Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study
Schetelig, J., Hoek, J., Stilgenbauer, S., Middeke, J. M., Andersen, N. S., Fox, C. P., Lenhoff, S., Volin, L., Shimoni, A., Schroyens, W., van Gelder, M., Bunjes, D., van Biezen, A., Baldauf, H., de Wreede, L. C., Tournilhac, O., Kröger, N., Yakoub-Agha, I. & Dreger, P., Jan 2022, In: Bone Marrow Transplantation. 57, 1, p. 144-144 1 p.
Research output: Contribution to journal › Erratum / corrigendum › Academic

Open Access

Cite this

Schetelig, J., Hoek, J., Stilgenbauer, S., Middeke, J. M., Andersen, N. S., Fox, C. P., Lenhoff, S., Volin, L., Shimoni, A., Schroyens, W., van Gelder, M., Bunjes, D., van Biezen, A., Baldauf, H., de Wreede, L. C., Tournilhac, O., Kroger, N., Yakoub-Agha, I., & Dreger, P. (2021). Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study. Bone Marrow Transplantation, 56(3), 692-695. https://doi.org/10.1038/s41409-020-01013-y

@article{b3dc50b0a5fb4314ba6e6a2f79579445,

title = "Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study",

keywords = "blood, cll, european-society, follow-up, retrospective analysis, CLL, FOLLOW-UP, RETROSPECTIVE ANALYSIS, EUROPEAN-SOCIETY, BLOOD",

author = "J. Schetelig and J. Hoek and S. Stilgenbauer and J.M. Middeke and N.S. Andersen and C.P. Fox and S. Lenhoff and L. Volin and A. Shimoni and W. Schroyens and \{van Gelder\}, M. and D. Bunjes and \{van Biezen\}, A. and H. Baldauf and \{de Wreede\}, L.C. and O. Tournilhac and N. Kroger and I. Yakoub-Agha and P. Dreger",

note = "Funding Information: Conflict of interest JS—consultancy honoraria from AstraZeneca, Janssen, Roche, Gilead, Abbvie, Sanofi, Molmed; lecture fees from AstraZeneca, Janssen, Roche, Gilead, Abbvie, Sanofi, Novartis; research support from Genzyme, Sanofi, GSK, Novartis, Abbvie. CPF—Speaker/consultancy honoraria and travel support from Janssen. SS—Honoraria for consultancy, Advisory board member, Speaker honoraria, Research grants, Travel support from AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann La-Roche, Janssen, Novartis. PD—consultancy for AbbVie, AstraZeneca, Gilead, Janssen, Novartis, Riemser, Roche; speakers bureau for AbbVie, Gilead, Novartis, Riemser, Roche; research support from Neovii and Riemser. The remaining authors declared no conflict of interest.",

year = "2021",

month = mar,

day = "1",

doi = "10.1038/s41409-020-01013-y",

language = "English",

volume = "56",

pages = "692--695",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Springer",

number = "3",

}

Schetelig, J, Hoek, J, Stilgenbauer, S, Middeke, JM, Andersen, NS, Fox, CP, Lenhoff, S, Volin, L, Shimoni, A, Schroyens, W, van Gelder, M, Bunjes, D, van Biezen, A, Baldauf, H, de Wreede, LC, Tournilhac, O, Kroger, N, Yakoub-Agha, I & Dreger, P 2021, 'Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study', Bone Marrow Transplantation, vol. 56, no. 3, pp. 692-695. https://doi.org/10.1038/s41409-020-01013-y

Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study. / Schetelig, J.; Hoek, J.; Stilgenbauer, S. et al.
In: Bone Marrow Transplantation, Vol. 56, No. 3, 01.03.2021, p. 692-695.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study

AU - Schetelig, J.

AU - Hoek, J.

AU - Stilgenbauer, S.

AU - Middeke, J.M.

AU - Andersen, N.S.

AU - Fox, C.P.

AU - Lenhoff, S.

AU - Volin, L.

AU - Shimoni, A.

AU - Schroyens, W.

AU - van Gelder, M.

AU - Bunjes, D.

AU - van Biezen, A.

AU - Baldauf, H.

AU - de Wreede, L.C.

AU - Tournilhac, O.

AU - Kroger, N.

AU - Yakoub-Agha, I.

AU - Dreger, P.

N1 - Funding Information: Conflict of interest JS—consultancy honoraria from AstraZeneca, Janssen, Roche, Gilead, Abbvie, Sanofi, Molmed; lecture fees from AstraZeneca, Janssen, Roche, Gilead, Abbvie, Sanofi, Novartis; research support from Genzyme, Sanofi, GSK, Novartis, Abbvie. CPF—Speaker/consultancy honoraria and travel support from Janssen. SS—Honoraria for consultancy, Advisory board member, Speaker honoraria, Research grants, Travel support from AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann La-Roche, Janssen, Novartis. PD—consultancy for AbbVie, AstraZeneca, Gilead, Janssen, Novartis, Riemser, Roche; speakers bureau for AbbVie, Gilead, Novartis, Riemser, Roche; research support from Neovii and Riemser. The remaining authors declared no conflict of interest.

PY - 2021/3/1

Y1 - 2021/3/1

KW - blood

KW - cll

KW - european-society

KW - follow-up

KW - retrospective analysis

KW - CLL

KW - FOLLOW-UP

KW - RETROSPECTIVE ANALYSIS

KW - EUROPEAN-SOCIETY

KW - BLOOD

U2 - 10.1038/s41409-020-01013-y

DO - 10.1038/s41409-020-01013-y

M3 - Comment/Letter to the editor

C2 - 32801318

SN - 0268-3369

VL - 56

SP - 692

EP - 695

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 3

ER -

Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study

Keywords

Access to Document

Research output

Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study

Cite this